Renal targeting of kinase inhibitors

International Journal of Pharmaceutics

Volumn 364, Issue 2, 2008, Pages 249-257

  Dolman, M E M ^a   Fretz, M M ^a   Segers, G J W ^a   Lacombe, M ^b   Prakash, J ^c   Storm, G ^a   Hennink, W E ^a   Kok, R J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Kreatech Biotechnology BV   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Coordination chemistry; Drug conjugate; Drug targeting; Kidney; Linker technology; Lysozyme

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA SMOOTH MUSCLE ACTIN; GEFITINIB; LYSOZYME; MITOGEN ACTIVATED PROTEIN KINASE P38; NITROGEN; PHOSPHOTRANSFERASE INHIBITOR; PLATINUM; PROCOLLAGEN; RHO KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VIMENTIN;

CHRONIC KIDNEY DISEASE; CONJUGATION; DERIVATIZATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; GENE EXPRESSION; GENE TARGETING; GLOMERULUS; GLOMERULUS FILTRATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET CELL;

ANIMALS; DRUG DELIVERY SYSTEMS; FIBROSIS; GENE TARGETING; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULES; MURAMIDASE; PROTEIN KINASE INHIBITORS;

EID: 55649116649     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.04.040     Document Type: Review

References (71)

1. Adams J.P., and Sweatt J.D. Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 135-163
2. Asgeirsdottir S.A., Kamps J.A., Bakker H.I., Zwiers P.J., Heeringa P., van der Weide K., van Goor H., Petersen A.H., Morselt H., Moorlag H.E., Steenbergen E., Kallenberg C.G., and Molema G. Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol. Pharmacol. 72 (2007) 121-131
3. Asgeirsdottir S.A., Zwiers P.J., Morselt H.W., Moorlag H.E., Bakker H.I., Heeringa P., Kok J.W., Kallenberg C.G., Molema G., and Kamps J.A. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am. J. Physiol. Renal Physiol. 294 (2008) F554-561
4. Baur B., and Baumgartner E.R. Na(+)-dependent biotin transport into brush-border membrane vesicles from human kidney cortex. Pflugers Arch. 422 (1993) 499-505
5. Bottinger E.P., and Bitzer M. TGF-beta signaling in renal disease. J. Am. Soc. Nephrol. 13 (2002) 2600-2610
6. Burns W.C., Kantharidis P., and Thomas M.C. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs 185 (2007) 222-231
7. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., Bawendi M.G., and Frangioni J.V. Renal clearance of quantum dots. Nat. Biotechnol. 25 (2007) 1165-1170
8. Christensen E.I., and Verroust P.J. Megalin and cubilin, role in proximal tubule function and during development. Pediatr. Nephrol. 17 (2002) 993-999
9. Cignarelli M., and Lamacchia O. Obesity and kidney disease. Nutr. Metab. Cardiovasc. Dis. 17 (2007) 757-762
10. De Borst M., Prakash J., Melenhorst W., van den Heuvel M., Kok R., Navis G., and van Goor H. Glomerular and tubular induction of the transcription factor c-Jun in human renal disease. J. Pathol. 213 (2007) 219-228
11. de Cassia da Silveira E.S.R., and de Oliveira Guerra M. Reproductive toxicity of lapachol in adult male Wistar rats submitted to short-term treatment. Phytother. Res. 21 (2007) 658-662
12. Docherty N.G., O'Sullivan O.E., Healy D.A., Murphy M., O'Neill A.J., Fitzpatrick J.M., and Watson R.W. TGF-beta1-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation. Am. J. Physiol. Renal Physiol. 290 (2006) F1202-F1212
13. Eddy A.A. Molecular basis of renal fibrosis. Pediatr. Nephrol. 15 (2000) 290-301
14. El Nahas M.A., and Bello A.K. Chronic kidney disease: the global challenge. Lancet 365 (2005) 331-340
15. Eskens F.A., and Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur. J. Cancer 42 (2006) 3127-3139
16. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L., Grotzfeld R.M., Herrgard S., Insko D.E., Insko M.A., Lai A.G., Lelias J.M., Mehta S.A., Milanov Z.V., Velasco A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., and Lockhart D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
17. Fan J.M., Ng Y.Y., Hill P.A., Nikolic-Paterson D.J., Mu W., Atkins R.C., and Lan H.Y. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int. 56 (1999) 1455-1467
18. Fernandez A., Sanguino A., Peng Z., Ozturk E., Chen J., Crespo A., Wulf S., Shavrin A., Qin C., Ma J., Trent J., Lin Y., Han H.D., Mangala L.S., Bankson J.A., Gelovani J., Samarel A., Bornmann W., Sood A.K., and Lopez-Berestein G. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J. Clin. Invest. 117 (2007) 4044-4054
19. Force T., Krause D.S., and Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7 (2007) 332-344
20. Francois H., Placier S., Flamant M., Tharaux P.L., Chansel D., Dussaule J.C., and Chatziantoniou C. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J. 18 (2004) 926-928
21. Fretz, M.M., Prakash, J., Dolman, M.E.M., Lacombe, M., de Borst, M.H., van Goor, H., Poelstra, K., Kok, R.J., 2007. Renal Delivery of Kinase Inhibitors Ameliorates Experimental Inflammation and Fibrosis. ASN Renal Week 2007, October 31-November 5 Abstract SU-FC141.
22. Ghandehari H. Polymer-peptide conjugates for targeted delivery to sites of angiogenesis. European Symposium on Controlled Drug Delivery. Noordwijk, The Nederlands, April 2-4 2008 (2008)
23. Gonzalo T., Beljaars L., van de Bovenkamp M., Temming K., van Loenen A.M., Reker-Smit C., Meijer D.K., Lacombe M., Opdam F., Keri G., Orfi L., Poelstra K., and Kok R.J. Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. J. Pharmacol. Exp. Ther. 321 (2007) 856-865
24. Gonzalo T., Talman E.G., van de Ven A., Temming K., Greupink R., Beljaars L., Reker-Smit C., Meijer D.K., Molema G., Poelstra K., and Kok R.J. Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. J. Control Release 111 (2006) 193-203
25. Haas M., de Zeeuw D., van Zanten A., and Meijer D.K. Quantification of renal low-molecular-weight protein handling in the intact rat. Kidney Int. 43 (1993) 949-954
26. Haas M., Kluppel A.C., Wartna E.S., Moolenaar F., Meijer D.K., de Jong P.E., and de Zeeuw D. Drug-targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo. Kidney Int. 52 (1997) 1693-1699
27. Han D.C., Hoffman B.B., Hong S.W., Guo J., and Ziyadeh F.N. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am. J. Physiol. Renal Physiol. 278 (2000) F628-F634
28. Harper S.J., and LoGrasso P. Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell Signal. 13 (2001) 299-310
29. Hayashi K., Wakino S., Kanda T., Homma K., Sugano N., and Saruta T. Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. J. Pharmacol. Sci. 100 (2006) 29-33
30. Isaka Y. Gene therapy targeting kidney diseases: routes and vehicles. Clin. Exp. Nephrol. 10 (2006) 229-235
31. Iseki K. Factors influencing the development of end-stage renal disease. Clin. Exp. Nephrol. 9 (2005) 5-14
32. Kamada H., Tsutsumi Y., Sato-Kamada K., Yamamoto Y., Yoshioka Y., Okamoto T., Nakagawa S., Nagata S., and Mayumi T. Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting. Nat. Biotechnol. 21 (2003) 399-404
33. Keri G., Szekelyhidi Z., Banhegyi P., Varga Z., Hegymegi-Barakonyi B., Szantai-Kis C., Hafenbradl D., Klebl B., Muller G., Ullrich A., Eros D., Horvath Z., Greff Z., Marosfalvi J., Pato J., Szabadkai I., Szilagyi I., Szegedi Z., Varga I., Waczek F., and Orfi L. Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology. Assay Drug Dev. Technol. 3 (2005) 543-551
34. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F.J., Rosenzweig A., Salomon R.N., Van Etten R.A., Alroy J., Durand J.B., and Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12 (2006) 908-916
35. Kissel M., Peschke P., Subr V., Ulbrich K., Strunz A.M., Kuhnlein R., Debus J., and Friedrich E. Detection and cellular localisation of the synthetic soluble macromolecular drug carrier pHPMA. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) 1055-1062
36. Kobayashi H., Jo S.K., Kawamoto S., Yasuda H., Hu X., Knopp M.V., Brechbiel M.W., Choyke P.L., and Star R.A. Polyamine dendrimer-based MRI contrast agents for functional kidney imaging to diagnose acute renal failure. J. Magn. Reson. Imaging 20 (2004) 512-518
37. Kobayashi H., Kawamoto S., Jo S.K., Bryant Jr. H.L., Brechbiel M.W., and Star R.A. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug. Chem. 14 (2003) 388-394
38. Kobayashi H., Sato N., Kawamoto S., Saga T., Hiraga A., Ishimori T., Konishi J., Togashi K., and Brechbiel M.W. Novel intravascular macromolecular MRI contrast agent with generation-4 polyamidoamine dendrimer core: accelerated renal excretion with coinjection of lysine. Magn. Reson. Med. 46 (2001) 457-464
39. Kodaira H., Tsutsumi Y., Yoshioka Y., Kamada H., Kaneda Y., Yamamoto Y., Tsunoda S., Okamoto T., Mukai Y., Shibata H., Nakagawa S., and Mayumi T. The targeting of anionized polyvinylpyrrolidone to the renal system. Biomaterials 25 (2004) 4309-4315
40. Kok R.J., Grijpstra F., Walthuis R.B., Moolenaar F., de Zeeuw D., and Meijer D.K. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme. J. Pharmacol. Exp. Ther. 288 (1999) 281-285
41. Koopman R.J., Mainous III A.G., Diaz V.A., and Geesey M.E. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann. Fam. Med. 3 (2005) 60-63
42. Laping N.J. ALK5 inhibition in renal disease. Curr. Opin. Pharmacol. 3 (2003) 204-208
43. Levey A.S., Eckardt K.U., Tsukamoto Y., Levin A., Coresh J., Rossert J., De Zeeuw D., Hostetter T.H., Lameire N., and Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 67 (2005) 2089-2100
44. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 69 (2006) 213-217
45. Madhusudan S., and Ganesan T.S. Tyrosine kinase inhibitors in cancer therapy. Clin. Biochem. 37 (2004) 618-635
46. Masuda T., Ide N., and Kitabatake N. Effects of chemical modification of lysine residues on the sweetness of lysozyme. Chem. Senses 30 (2005) 253-264
47. Prakash, J., de Borst, M.H., Lacombe, M., Opdam, F., Klok, P.A., van Goor, H., Meijer, D.K., Moolenaar, F., Poelstra, K., Kok, R.J., 2008c. Renally targeted Y27632 inhibits ischemia/reperfusion-induced tubular damage, inflammation and fibrosis. JASN, accepted.
48. Prakash J., de Borst M.H., van Loenen-Weemaes A.M., Lacombe M., Opdam F., van Goor H., Meijer D.K., Moolenaar F., Poelstra K., and Kok R.J. Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Pharm. Res. 25 (2008) 2427-2439
49. Prakash J., Poelstra K., van Goor H., Moolenaar F., Meijer D.K., and Kok R.J. Novel therapeutic targets for the treatment of tubulointerstitial fibrosis. Curr. Signal Trans. Ther. 3 (2008) 97-111
50. Prakash J., Saluja V., Visser J., Moolenaar F., Meijer D.K., Poelstra K., and Kok R.J. Bioanalysis and pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 826 (2005) 220-225
51. Prakash J., Sandovici M., Saluja V., Lacombe M., Schaapveld R.Q., de Borst M.H., van Goor H., Henning R.H., Proost J.H., Moolenaar F., Keri G., Meijer D.K., Poelstra K., and Kok R.J. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis. J. Pharmacol. Exp. Ther. 319 (2006) 8-19
52. Prakash J., van Loenen-Weemaes A.M., Haas M., Proost J.H., Meijer D.K., Moolenaar F., Poelstra K., and Kok R.J. Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme. Drug Metab. Dispos. 33 (2005) 683-688
53. Razzaque M.S., Ahsan N., and Taguchi T. Role of apoptosis in fibrogenesis. Nephron 90 (2002) 365-372
54. Reedijk J. Metal-ligand exchange kinetics in platinum and ruthenium complexes. Platinum Met. Rev. 52 (2008) 2-11
55. Ross J.S., Schenkein D.P., Pietrusko R., Rolfe M., Linette G.P., Stec J., Stagliano N.E., Ginsburg G.S., Symmans W.F., Pusztai L., and Hortobagyi G.N. Targeted therapies for cancer 2004. Am. J. Clin. Pathol. 122 (2004) 598-609
56. Rubenstein A.H. Obesity: a modern epidemic. Trans. Am. Clin. Climatol. Assoc. 116 (2005) 103-111 (discussion 112-103)
57. Ryan T.P., Sloand J.A., Winters P.C., Corsetti J.P., and Fisher S.G. Chronic kidney disease prevalence and rate of diagnosis. Am. J. Med. 120 (2007) 981-986
58. Salmain M., Blais J.C., Tran-Huy H., Compain C., and Jaouen G. Reaction of hen egg white lysozyme with Fischer-type metallocarbene complexes. Characterization of the conjugates and determination of the metal complex binding sites. Eur. J. Biochem. 268 (2001) 5479-5487
59. Sharpe C.C., and Hendry B.M. Signaling: focus on Rho in renal disease. J. Am. Soc. Nephrol. 14 (2003) 261-264
60. Strutz F., and Neilson E.G. New insights into mechanisms of fibrosis in immune renal injury. Springer Semin. Immunopathol. 24 (2003) 459-476
61. Temming K., Fretz M.M., and Kok R.J. Organ- and cell-type specific delivery of kinase inhibitors: a novel approach in the development of targeted drugs. Curr. Mol. Pharmacol. 1 (2008) 1-12
62. Temming K., Lacombe M., Schaapveld R.Q.J., Orfi L., Keri G., Poelstra K., Molema G., and Kok R.J. Rational design of RGDalbumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium. Chem. Med. Chem. 11 (2006) 1200-1203
63. Temming K., Lacombe M., van der Hoeven P., Prakash J., Gonzalo T., Dijkers E.C., Orfi L., Keri G., Poelstra K., Molema G., and Kok R.J. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology. Bioconjug. Chem. 17 (2006) 1246-1255
64. Teske C.A., Simon R., Niebisch A., and Hubbuch J. Changes in retention behavior of fluorescently labeled proteins during ion-exchange chromatography caused by different protein surface labeling positions. Biotechnol. Bioeng. 98 (2007) 193-200
65. Tuffin G., Huwyler J., Waelti E., Hammer C., and Marti H.P. Drug targeting using OX7-immunoliposomes: correlation between Thy1.1 antigen expression and tissue distribution in the rat. J. Drug Target 16 (2008) 156-166
66. Tuffin G., Waelti E., Huwyler J., Hammer C., and Marti H.P. Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J. Am. Soc. Nephrol. 16 (2005) 3295-3305
67. van der Wouden E.A., Sandovici M., Henning R.H., de Zeeuw D., and Deelman L.E. Approaches and methods in gene therapy for kidney disease. J. Pharmacol. Toxicol. Methods 50 (2004) 13-24
68. Vlahos C.J., McDowell S.A., and Clerk A. Kinases as therapeutic targets for heart failure. Nat. Rev. Drug Discov. 2 (2003) 99-113
69. Windt W.A., Prakash J., Kok R.J., Moolenaar F., Kluppel C.A., de Zeeuw D., van Dokkum R.P., and Henning R.H. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis. J. Renin Angiotensin Aldosterone Syst. 5 (2004) 197-202
70. Yuan Z.X., Sun X., Gong T., Ding H., Fu Y., and Zhang Z.R. Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier. J. Drug Target 15 (2007) 269-278
71. Zhang M., Tang J., and Li X. Interleukin-1beta-induced transdifferentiation of renal proximal tubular cells is mediated by activation of JNK and p38 MAPK. Nephron. Exp. Nephrol. 99 (2005) e68-e76